PortfoliosLab logoPortfoliosLab logo
Sana Biotechnology, Inc. (SANA)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US7995661045
CUSIP
799566104
IPO Date
Feb 4, 2021

Highlights

Market Cap
$729.31M
Enterprise Value
$751.24M
EPS (TTM)
-$0.97
EBITDA (TTM)
-$250.32M
Year Range
$1.26 - $6.55
Target Price
$8.00
ROA (TTM)
-58.57%
ROE (TTM)
-151.77%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Sana Biotechnology, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Sana Biotechnology, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Sana Biotechnology, Inc. (SANA) has returned -29.24% so far this year and 71.43% over the past 12 months.


Sana Biotechnology, Inc.

1D
7.46%
1M
-31.59%
YTD
-29.24%
6M
-18.87%
1Y
71.43%
3Y*
-4.14%
5Y*
-38.22%
10Y*

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Feb 4, 2021, SANA's average daily return is +0.04%, while the average monthly return is -0.48%.

Historically, 35% of months were positive and 65% were negative. The best month was Jan 2025 with a return of +97.6%, while the worst month was Jan 2022 at -43.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 6 months.

On a daily basis, SANA closed higher 46% of trading days. The best single day was Jan 8, 2025 with a return of +160.6%, while the worst single day was Aug 7, 2025 at -30.1%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20268.85%-4.97%-31.59%-29.24%
202597.55%-18.94%-35.63%13.10%14.21%25.81%48.72%-24.63%16.01%39.44%-13.13%-5.35%149.69%
202434.56%82.88%-0.40%-10.00%-16.67%-27.20%11.54%-0.66%-31.24%-15.87%-20.57%-41.37%-60.05%
202315.44%-19.52%-10.90%61.77%13.80%-1.00%-1.68%-8.70%-27.66%-23.51%37.16%0.49%3.29%
2022-43.41%-26.26%27.86%-8.60%-32.05%25.34%3.89%1.95%-11.89%-3.33%-13.97%-20.84%-74.48%
2021-12.42%8.88%-35.76%-2.47%-6.25%-17.14%47.27%-6.13%-7.90%-8.34%-18.57%-55.90%

Benchmark Metrics

Sana Biotechnology, Inc. has an annualized alpha of -14.64%, beta of 2.13, and R² of 0.09 versus S&P 500 Index. Calculated based on daily prices since February 05, 2021.

  • This stock participated in 239.91% of S&P 500 Index downside but only 116.88% of its upside — more exposed to losses than it benefited from rallies.
  • R² of 0.09 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-14.64%
Beta
2.13
0.09
Upside Capture
116.88%
Downside Capture
239.91%

Return for Risk

Risk / Return Rank

SANA ranks 67 for risk / return — better than 67% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.


SANA Risk / Return Rank: 6767
Overall Rank
SANA Sharpe Ratio Rank: 6464
Sharpe Ratio Rank
SANA Sortino Ratio Rank: 7171
Sortino Ratio Rank
SANA Omega Ratio Rank: 6767
Omega Ratio Rank
SANA Calmar Ratio Rank: 6767
Calmar Ratio Rank
SANA Martin Ratio Rank: 6464
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Sana Biotechnology, Inc. (SANA) and compare them to a chosen benchmark (S&P 500 Index).


SANABenchmarkDifference

Sharpe ratio

Return per unit of total volatility

0.68

0.90

-0.22

Sortino ratio

Return per unit of downside risk

1.69

1.39

+0.30

Omega ratio

Gain probability vs. loss probability

1.20

1.21

-0.01

Calmar ratio

Return relative to maximum drawdown

1.25

1.40

-0.15

Martin ratio

Return relative to average drawdown

2.59

6.61

-4.02

Explore SANA risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Sana Biotechnology, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Sana Biotechnology, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Sana Biotechnology, Inc. was 96.92%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current Sana Biotechnology, Inc. drawdown is 93.38%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-96.92%Feb 11, 20211044Apr 8, 2025
-2.35%Feb 8, 20211Feb 8, 20211Feb 9, 20212

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Sana Biotechnology, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Sana Biotechnology, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for SANA in comparison with other companies in the Biotechnology industry. Currently, SANA has a P/B value of 4.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items